Online citations, reference lists, and bibliographies.
← Back to Search

Glomerular Filtration Rate Is A Confounder For The Measurement Of Soluble Mesothelin In Serum.

K. Hollevoet, D. Bernard, F. De Geeter, N. Walgraeve, A. van den Eeckhaut, R. Vanholder, C. van de Wiele, V. Stove, J. Van Meerbeeck, J. Delanghe
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The mesothelin gene encodes a 71-kDa precursor protein that is subsequently cleaved into a soluble megakaryocyte potentiating factor and a membrane-bound part, mesothelin. Mesothelin can be shed as “soluble mesothelin” or “soluble mesothelin-related protein” (SMRP),1 which is an approximately 40-kDa biomarker of malignant mesothelioma, an asbestos-related cancer (1). Mesothelioma typically occurs in middle-aged men, and the renal function or the glomerular filtration rate (GFR) can occasionally decrease in these patients and in individuals at risk of developing mesothelioma. Renal impairment leads to the accumulation of low molecular weight proteins in the blood [e.g., cystatin C (13 kDa) and β-trace protein (BTP) (23–29 kDa)], and these proteins have been used as markers of the GFR. Such renal impairment can also cause the accumulation of soluble mesothelin, as has previously been reported for a limited number of cases(2). Our aim, therefore, was to thoroughly investigate the impact of renal function on serum SMRP concentrations. We enrolled 66 individuals (49 men and 17 women; median age, 58 years; range, 24–80 years), who were referred for measurement of 51Cr-EDTA clearance to estimate the GFR. We excluded patients with asbestos-related diseases/malignancies, patients with endometrial, ovarian, cervix, lung, breast, pancreatic, or gastrointestinal cancer, and patients with leukemia, because these conditions can overexpress mesothelin (3)(4). The study was approved by the ethics committee of both participating hospitals, and participants gave written informed consent. …
This paper references
10.1002/0471142727.mb0409s67
Analysis of RNA by Northern and Slot Blot Hybridization
T. Brown (2004)
MESOMARKTM: a potential test for malignant pleural mesothelioma
HL Beyer (2007)
10.1016/J.CCA.2005.11.005
Pediatric brain natriuretic peptide and N-terminal pro-brain natriuretic peptide reference intervals.
S. Soldin (2006)
Kenyan crossroads: migration and gene flow in six ethnic groups from Eastern Africa.
L. Castrí (2008)
10.1093/JAT/32.7.516
Urinary buprenorphine concentrations in patients treated with suboxone as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay.
M. J. Hull (2008)
10.1373/CLINCHEM.2006.079327
MESOMARK: a potential test for malignant pleural mesothelioma.
H. L. Beyer (2007)
MESOMARKTM: a potential test for malignant pleural mesothelioma
HL Beyer (2007)
MESOMARK TM : a potential test for malignant pleural mesothelioma
JS Fleming (2007)
10.1016/S0894-7317(89)80014-8
Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.
N. Schiller (1989)
10.1373/CLINCHEM.2007.089995
Evaluation of analytical performance of the Siemens ADVIA TnI ultra immunoassay.
C. Prontera (2007)
10.1158/1078-0432.CCR-05-1477
Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer
R. Hassan (2006)
10.1073/PNAS.96.20.11531
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
N. Scholler (1999)
10.1002/ELPS.200390036
DNA fragment analysis by an affordable multiple‐channel capillary electrophoresis system
M. S. Liu (2003)
10.1007/s00246-008-9258-4
NT-Pro-B-type Natriuretic Peptide in Infants and Children: Reference Values Based on Combined Data from Four Studies
A. Nir (2008)
10.1373/CLINCHEM.2003.024760
Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review.
A. Clerico (2004)
10.1007/s00439-005-1322-z
Microsatellite variation and evolution of human lactase persistence
M. Coelho (2005)
10.7326/0003-4819-145-4-200608150-00004
Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate
A. Levey (2006)
10.1016/j.cca.2007.12.020
Clinical relevance of measurement of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in pediatric cardiology.
M. Cantinotti (2008)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1007/BF02258429
Comparison of radionuclide estimation of glomerular filtration rate using technetium 99m diethylenetriaminepentaacetic acid and chromium 51 ethylenediaminetetraacetic acid
J. Fleming (2005)
10.1373/CLINCHEM.2005.048496
Comparison of a fully automated immunoassay with a point-of-care testing method for B-type natriuretic peptide.
C. Prontera (2005)
10.1016/0002-9149(86)90771-X
Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.
R. Devereux (1986)



This paper is referenced by
10.1016/b978-0-12-394384-2.00006-1
Asbestos-Related Disease
J. R. Portal (2012)
10.5301/JBM.2011.8332
Two Novel Polymorphisms in 5' Flanking Region of the Mesothelin Gene are Associated with Soluble Mesothelin-Related Peptide (SMRP) Levels
A. Cristaudo (2011)
10.1097/JTO.0b013e3181e392d7
Sensitivity of Urinary Mesothelin in Patients with Malignant Mesothelioma
J. Creaney (2010)
10.1515/cclm-2012-0314
A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels
E. Park (2012)
10.1007/978-3-030-53908-5
The International System for Serous Fluid Cytopathology
A. Chandra (2020)
10.1074/mcp.M113.030775
Proteome Screening of Pleural Effusions Identifies Galectin 1 as a Diagnostic Biomarker and Highlights Several Prognostic Biomarkers for Malignant Mesothelioma*
Filip Mundt (2013)
10.1093/carcin/bgz103
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Christina Gillezeau (2019)
10.1136/bmjopen-2017-017104
Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study
S. Casjens (2017)
10.1038/s41598-018-32315-3
Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin – a case-control comparison nested into a prospective cohort of asbestos-exposed workers
G. Johnen (2018)
10.1515/CCLM.2010.165
Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population
Eun-Kee Park (2010)
10.4137/BMI.S3927
Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum
D. Weber (2010)
10.1007/s00408-013-9526-9
Serum Biomarkers in Patients with Mesothelioma and Pleural Plaques and Healthy Subjects Exposed to Naturally Occurring Asbestos
Mehmet Bayram (2013)
10.1016/j.cllc.2011.12.004
Mesothelin levels in urine are affected by glomerular leakage and tubular reabsorption.
K. Hollevoet (2012)
10.1159/000355687
Is Soluble Mesothelin-Related Protein an Upfront Predictive Marker of Pleural Mesothelioma? A Prospective Study on Italian Workers Exposed to Asbestos
R. Filiberti (2013)
um Mesothelin for Early Detection of Asbestos-Induced B & P cer Malignant Mesothelioma
te Creaney (2010)
10.1056/NEJMc1213514
Fibulin-3 as a biomarker for pleural mesothelioma.
K. Hollevoet (2013)
10.1155/2014/413946
Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
J. Creaney (2014)
10.4225/23/5976d9b9cabf2
The diagnostic potential and biological significance of MicroRNA in Malignant Pleural Mesothelioma
Kimberly A. Birnie (2016)
10.1158/1055-9965.EPI-10-0346
Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma
J. Creaney (2010)
10.1183/09031936.00148211
A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions
C. Hooper (2012)
10.1016/j.lungcan.2013.09.016
Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
J. Creaney (2013)
10.2217/bmm.11.18
Soluble markers for diagnosis of malignant pleural mesothelioma.
A. Cristaudo (2011)
highlights several prognostic biomarkers for malignant mesothelioma.
Filip Mundt (2013)
10.1097/JTO.0b013e31820db377
Serial Measurements of Mesothelioma Serum Biomarkers in Asbestos-Exposed Individuals: A Prospective Longitudinal Cohort Study
K. Hollevoet (2011)
10.1378/chest.11-0129
The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.
Kevin Hollevoet (2012)
Malignant pleural mesothelioma : novel biomarkers and related pathways
Filip Mundt (2013)
10.1136/oemed-2016-104024
Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals
C. De Santi (2017)
10.1016/j.lungcan.2011.01.011
Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening.
N. Boudville (2011)
10.1183/09031936.00226111
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma
I. Pantazopoulos (2012)
10.7150/ijms.23939
Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population
G. Aguilar‐Madrid (2018)
10.1097/JTO.0b013e3182272294
Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma
K. Hollevoet (2011)
Semantic Scholar Logo Some data provided by SemanticScholar